Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eisai has signed a statement of intent with the World Health Organization (WHO) to supply free of charge of a primary medicine for the treatment of lymphatic filariasis.
Subscribe to our email newsletter
In the statement of intent, Eisai agreed to produce and supply to WHO free of charge up to 2.2 billion 100mg tablets of diethylcarbamazine (generic name, DEC), a medicine used to treat lymphatic filariasis, in accordance with the high quality standards of WHO, over a six year period between 2012 and 2017.
Eisai said that this is in line with WHOs forecast for the number of DEC tablets needed to help eliminate lymphatic filariasis in epidemic countries over this period.
Production of the medicine is planned at Eisais Vizag Plant in India.
Eisai is working with WHO to finalise details of this program with the aim of executing an official contract with WHO in the near future.